Clinical Scorecard: Comparative Analysis of BTK Inhibitors Versus Lenalidomide for First-Line Maintenance in Primary CNS Lymphoma: A Multi-Center Retrospective Investigation

At a Glance

Key Highlights

• High-dose methotrexate-based induction therapy followed by consolidation with ASCT or WBRT improves survival but has limitations in real-world applicability.
• BTK inhibitors (ibrutinib, zanubrutinib, orelabrutinib) and lenalidomide show promise as maintenance therapies to prolong remission and reduce relapse in PCNSL.
• Maintenance therapy is recommended for at least 24 months post-induction or ASCT, with regular MRI and CSF monitoring every 3 months initially.

Guideline-Based Recommendations

Diagnosis

• Histological confirmation of PCNSL (diffuse large B-cell lymphoma) with lesions confined to CNS by contrast-enhanced MRI.
• Use of International Extranodal Lymphoma Study Group (IELSG) score for risk stratification.

Management

• Induction with 4–6 cycles of high-dose methotrexate-based immunochemotherapy, optionally combined with rituximab and cytarabine or other agents.
• Consolidation with autologous stem cell transplantation (ASCT) for medically suitable patients.
• Maintenance therapy with BTK inhibitors (ibrutinib 560 mg/day, zanubrutinib 320 mg/day, or orelabrutinib 150 mg/day) or lenalidomide (25 mg/day for 21 days every 28-day cycle) initiated after induction or ASCT.
• Intrathecal methotrexate (10 mg) every 3 months during maintenance.

Monitoring & Follow-up

• Tumor response assessment by contrast-enhanced MRI and CSF cytology after induction, before maintenance, and during maintenance every 3 months for 2 years, then annually.
• Use of 18F-Fluoro-Ethyl-Tyrosine PET scan prior to maintenance to evaluate residual disease.
• Monitoring for disease progression per International Primary CNS Lymphoma Collaborative Group (IPCG) criteria.

Risks

• Potential toxicity and intolerance to BTK inhibitors or lenalidomide requiring treatment adjustment or discontinuation.
• Relapse risk despite maintenance therapy necessitating close surveillance.
• Limitations of ASCT applicability due to comorbidities, patient preference, and socioeconomic factors.

Patient & Prescribing Data

Adults ≥18 years with newly diagnosed PCNSL achieving CR or PR post-induction therapy

Maintenance therapy choice depends on induction response, patient tolerance, and socioeconomic considerations; no switches between different BTK inhibitors during maintenance; maintenance duration recommended for minimum 24 months or until progression/toxicity

Clinical Best Practices

• Select maintenance therapy based on individual patient factors including response to induction, comorbidities, and treatment adherence potential.
• Ensure regular imaging and CSF monitoring to detect early relapse or progression.
• Administer intrathecal methotrexate every 3 months during maintenance to reduce CNS relapse risk.
• Consider ASCT consolidation in eligible patients to improve long-term outcomes.
• Maintain multidisciplinary coordination for treatment planning and toxicity management.

References

• NCCN Guidelines for Primary CNS Lymphoma
• International Primary CNS Lymphoma Collaborative Group (IPCG) Response Criteria
• ClinicalTrials.gov NCT04120350
• Chinese Clinical Trial Registry ChiCTR1900027811